BioSpace News Archive

Partnership advances innovation and increases precision of liver-directed oncology therapies for patients WOBURN, Mass. , Feb. 12, 2020 /PRNewswire/ -- Sirtex Medical , a leading manufacturer of targeted liver cancer therapies, today announced a collaboration with MIM Software Inc., a leading global provider of practical imaging solutions in the fields of radiation

MIM Software Inc., a leading global provider of medical imaging software, announced today a collaboration with Sirtex Medical, a leading manufacturer of targeted liver cancer therapies, that will provide patient-specific dosimetry of Yttrium-90 (Y-90) microspheres globally.

WorkFusion, a top provider of Intelligent Automation software, has just been recognized by HFS Research in its new “HFS Top Robotic Process Automation (RPA) Software Products 2020” report.

Dr. Laurence Klotz M.D., FRCSC, CM, the Chief Medical Officer of miR Scientific LLC, will present the results of the recently completed Case-Control validation study of 1,436 patients consisting of 836 patients in a fully cross-validated training group and independent testing group of 600 patients

Orthopaedic & Neurosurgery Specialists (ONS), one of the nation’s leading providers of orthopaedic and neurosurgery services, announced today that Timothy F. Corvino, M.D., has been named Chief Executive Officer of the organization, effective March 1.

Feb. 12, 2020 14:05 UTC Novel MRI system is a breakthrough in patient accessibility and cost GUILFORD, Conn.--( BUSINESS WIRE )-- Hyperfine Research, Inc. announced today that it has received US Food & Drug Administration 510(k) clearance for the world’s first bedside Magnetic Resonance Imaging (MRI) system, clearing the way for device shipments this summer. The Hyperfine system is 20X lower cost, 35X lower power consumption, and 10X lower weight than today’s fixed conv

SCOTTSDALE, Ariz. , Feb. 12, 2020 /PRNewswire/ -- Plasmology4 ® , Inc., a leader in Plasma Medicine, announced that the company’s product has been granted into the U.S. Food and Drug Administration’s (FDA) Breakthrough Devices Program for the treatment of “multidrug-refractory bacterial and/or fungal pathogen bioburden in a wound bed.”

VANCOUVER and MINNEAPOLIS, Feb. 12, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Neovasc, Inc. (“Neovasc” or the “Company”) ( NASDAQ , TSX : NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today achievement of design freeze for its fully retrievable transfemoral trans-septal Tiara™ (“TF/TS Tiara”) system, including a modified, lo

Beroni Group, an international diversified biopharmaceutical enterprise focused on the research, development, innovation and commercialization of therapies and products for treatment of global diseases, is pleased to announce that Marble Arch Research Inc., a leading independent equity research provider, has produced a new investment research report on the Company.

NEW YORK and SYDNEY , Feb. 12, 2020 /PRNewswire/ -- EnGeneIC Limited , a clinical-stage biopharmaceutical company advancing its proprietary EDV™ nanocell platform for targeted cyto-immunotherapy in cancer, today announced that the Company was featured in the publication InsightsCare